Patents Assigned to CATALYST PHARMACEUTICAL PARTNERS, INC.
  • Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
    Patent number: 9254274
    Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 9, 2016
    Assignees: Catalyst Pharmaceutical Partners, Inc., New York University, Feinstein Institute for Medical Research
    Inventors: Steven Miller, Jonathan D. Brodie, Stephen Dewey
  • METHODS OF USING (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID
    Publication number: 20130041028
    Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
    Type: Application
    Filed: February 25, 2011
    Publication date: February 14, 2013
    Applicants: NORTHWESTERN UNIVERSITY, CATALYST PHARMACEUTICAL PARTNERS, INC., BROOKHAVEN SCIENCE ASSOCIATES
    Inventors: Richard B. Silverman, Stephen L. Dewey, Steven Miller